European healthcare is one of the most globally significant equity sectors outside the US — and one of the most strategically diverse. The continent is home to large-cap pharmaceutical giants (Novo Nordisk, AstraZeneca, Roche, Novartis, Sanofi, GSK), world-class medtech companies (Fresenius, Siemens Healthineers, Getinge, Elekta), and a deep pool of under-covered biotech and speciality pharma companies. For investors seeking defensive growth, pricing power, and resilience across economic cycles, European healthcare is a core allocation.
Last updated: June 2026.
The structure of European healthcare equities
European listed healthcare divides into four distinct segments that screen very differently:
1. Large-cap integrated pharma — diversified drug portfolios, massive R&D pipelines, defensive but not cheap. Examples: Novo Nordisk, AstraZeneca, Roche, Novartis, Sanofi, GSK, UCB, Bayer.
2. Medical devices and equipment (medtech) — capital equipment for hospitals, recurring consumable revenue. Examples: Siemens Healthineers, Fresenius Medical Care, Coloplast, Getinge, Elekta, Carl Zeiss Meditec.
3. Speciality pharma and generics — focused drug portfolios, M&A-driven growth, often cheaper multiples. Examples: Ipsen, Recordati, Almirall, Stada (private).
4. Biotech — often pre-profit, valued on pipeline probability, requires different analytical framework entirely. Examples: Genmab, argenx, Galapagos, BioNTech.
Each segment requires different screening logic.
Screening large-cap European pharma
Large-cap pharma companies screen poorly on value metrics because they are almost never cheap by P/E, EV/EBITDA, or P/B. They trade at premium multiples because their pipelines, IP, and brand moats justify it.
The right approach for large-cap pharma:
EV/Sales — Sales multiples are more meaningful than earnings multiples for pharma because earnings are distorted by R&D investment cycles, patent cliffs, and one-off items. A pharma company investing heavily for future growth will look expensive on P/E but fair on EV/Sales.
EBIT margin — Large-cap pharma typically generates 20–35% EBIT margins. Below 15% signals a company undergoing significant R&D investment or facing competitive pressure.
Revenue growth — Pipeline productivity is reflected in top-line growth. Revenue growth above 8–10% suggests a company with productive recent launches; below 5% signals a patent-cliff-dominated business.
Dividend yield + buybacks — Mature pharma companies return significant capital. Sanofi, Novartis, and GSK yield 3–5%; total shareholder yield (dividends + buybacks) is often 6–10%.
Large-cap pharma screen
| Filter | Value |
|---|---|
| Sector | Healthcare / Pharmaceuticals |
| Market cap | > €10B |
| EBIT margin | > 15% |
| Revenue growth (3yr) | > 5% |
| EV/Sales | < 5 |
| Dividend yield | > 2.5% |
| Sort by | EV/Sales ascending |
Screening European medtech companies
Medtech companies sit between industrials and pharma in their business model: capital equipment sales plus high-margin consumables and service contracts. Screening logic is closer to high-quality industrials.
EV/EBITDA: Works well for medtech — typically 15–25x for quality names, reflecting the defensiveness of the healthcare end-market and high switching costs.
Recurring revenue percentage: Companies where consumables and service represent 50%+ of revenue are more defensively valued than pure capital equipment sellers.
Gross margin: Medtech gross margins typically 50–70% — below this level suggests commoditisation of the core product.
ROIC: Medical device companies with strong ROIC (> 15%) are compounding value efficiently. Carl Zeiss Meditec, Coloplast, and Elekta consistently produce high ROIC.
Medtech screen
| Filter | Value |
|---|---|
| Sub-sector | Medical Devices / Equipment |
| Market cap | > €500M |
| EV/EBITDA | < 20 |
| Gross margin | > 45% |
| Operating margin | > 12% |
| ROIC | > 12% |
| Sort by | EV/EBITDA ascending |
The major European healthcare companies
Pharmaceutical giants
Novo Nordisk (Denmark) — Global leader in GLP-1 drugs (Ozempic, Wegovy) for diabetes and obesity. Revenue growth of 30–60% in 2023–2025. Trades at significant premium (P/E 30–50x). Not a value stock; a quality/growth stock with limited downside to fundamental thesis.
AstraZeneca (UK) — Resurgent global pharma with strong oncology, cardiovascular, and respiratory pipelines. One of the best-executing major pharma companies over the 2015–2026 period. UK-listed but operates globally.
Roche (Switzerland) — Diversified diagnostics and pharma; defensive earnings from diagnostics provide stability. Trades at modest premium to Swiss market average.
Novartis (Switzerland) — Following spin-off of Sandoz (generics) into a standalone entity, Novartis is now a focused innovative pharma company. Consistent dividend growth; defensive balance sheet.
Sanofi (France) — Large diversified European pharma with vaccine and immunology franchises. Restructuring toward higher-growth therapeutic areas. Dividend yield above 4%.
GSK (UK) — Vaccines, speciality medicines, and HIV franchise. Post-Haleon spinoff, GSK is a more focused biopharma. Dividend yield 3–5%.
Medtech leaders
Siemens Healthineers (Germany) — Medical imaging, laboratory diagnostics, and digital health. Majority-owned by Siemens AG. Global scale in CT, MRI, and PET imaging.
Fresenius Medical Care (Germany) — World's largest dialysis products and services company. Defensive business model; recurring revenue from dialysis patients. Undervalued relative to quality of the recurring revenue franchise.
Coloplast (Denmark) — World-class ostomy and urology device manufacturer. Consistently high ROIC (35%+), 20%+ operating margins. Trades at premium multiples reflecting quality.
Getinge (Sweden) — Surgical workflow, intensive care, and sterilisation equipment. Strong installed base in hospital infrastructure globally.
Elekta (Sweden) — Radiation therapy equipment for cancer treatment. Long-term structural demand from cancer incidence growth. Cyclicality from hospital capex timing.
Biotech
Genmab (Denmark) — Oncology-focused biotech with royalty income from Darzalex (daratumumab) plus own pipeline. Unusual biotech economics — significant royalty cash flow from a blockbuster drug funds further R&D.
argenx (Belgium/Netherlands) — Immunology biotech with Vyvgart (efgartigimod) approved for multiple indications. Moving from development to commercial stage.
UCB (Belgium) — Established speciality pharma/biotech hybrid; neurology and immunology focus. Consistent profitability distinguishes it from pure biotech.
Defensive characteristics of European healthcare
Healthcare equities have several properties that make them attractive for long-term portfolios:
Non-cyclical demand: People require insulin, cancer treatment, dialysis, and hip replacements regardless of economic conditions. Revenue visibility is higher than most sectors.
Pricing power: Pharmaceutical companies have limited direct price competition (IP protection, regulatory approval barriers). Drug pricing is politically sensitive but structurally supportive of margins.
Demographic tailwinds: Ageing European populations increase demand for pharmaceutical and medical device products on a structural multi-decade basis.
Currency diversification: European healthcare companies generate revenue globally — in USD, CNY, and JPY as well as EUR — providing natural currency diversification.
Key risks for European healthcare investors
Patent cliffs: Drugs face loss of exclusivity after patent expiry. A pharma company with 40–60% of revenue in drugs expiring within 5 years faces significant earnings headwinds.
Pipeline failure: Drug development fails at high rates. Even Phase 3 trials (the final step before approval) fail roughly 40–50% of the time. For smaller biotech companies, a single trial failure can destroy 50–90% of the company's value.
Drug pricing regulation: European governments price drugs through national health technology assessment bodies. Reimbursement decisions can significantly limit market access. In the US, increasing political pressure on drug pricing is a structural headwind.
Medtech reimbursement cycles: Hospital capex is sensitive to healthcare budget cycles. Medtech company revenues can lag economic cycles by 12–24 months as hospital procurement decisions are delayed.
Frequently asked questions
Which European pharma stocks pay the highest dividends?
Sanofi, Novartis, and GSK are among the most consistent European pharma dividend payers, typically yielding 3–5%. Roche has a long history of dividend growth. For medtech, companies like Fresenius Medical Care have paid steady dividends. In general, large-cap European pharma is more generous with dividends than US pharma, which has historically preferred buybacks.
Is Novo Nordisk still worth buying after its massive run?
Novo Nordisk's extraordinary appreciation (10x+ in five years) reflects genuine fundamental transformation — from a strong diabetes franchise to the world leader in the largest new drug category in decades (GLP-1). Whether it remains worth buying depends on whether GLP-1 market growth continues, competition from Eli Lilly (tirzepatide) is manageable, and the current premium valuation can be sustained. It is not a value stock — it is a quality/growth stock where the question is whether 30–50x P/E is justified by the pipeline's long-term earnings potential.
What is the best screener for European healthcare stocks?
A screener with full coverage of Swiss, UK, Danish, Belgian, French, German, and Swedish healthcare companies with reliable fundamental data across all capitalisation levels. For large-cap pharma: EV/Sales, EBIT margin, and revenue growth are the key filters. For medtech: EV/EBITDA and ROIC. For biotech: the standard filters are largely inapplicable — market cap and pipeline stage are more meaningful than profitability metrics.
Can I screen European biotech companies by fundamentals?
Most European biotech companies are pre-profit and cannot be meaningfully screened by standard fundamental metrics (P/E, EV/EBITDA, operating margin). The relevant filters for biotech are: market cap (> €200M for sufficient liquidity), cash runway (cash and equivalents vs. burn rate — not typically a screener field), and pipeline stage. Genmab and UCB are exceptions — established revenue and profitability make them screenable with standard fundamental filters.
Screen European healthcare stocks → — free, no account required. Filter by sector, market cap, EBIT margin, EV/Sales, and dividend yield across all European exchanges.